Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

Clinical trial NCT07778316 · RECRUITING

Trial details

NCT number: NCT07778316
Sponsor: Amgen
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Small Cell Lung Cancer

Start date: 2026-08-31
Primary completion: 2027-09-24
Enrollment: 400

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.